Aura Biosciences (AURA) Other financing activities (2020 - 2026)
Aura Biosciences' (AURA) quarterly Other financing activities came in at $123000.0 in Q1 2026, up 100.94% on a QoQ basis from -$13.1 million in Q3 2025.
Aura Biosciences (AURA) Other financing activities (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Other financing activities data on file, last reported at $123000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $123000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 10.08% YoY) and the FY2025 annual result came in at $1.0 million, down 28.77% from the prior year.
- Other financing activities rose to $123000.0 in Q1 2026, from -$13.1 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $14.2 million in Q2 2025 to a low of -$13.1 million in Q3 2025.
- A 5-year average of $239153.8 and a median of $123000.0 in 2026 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 22569.84% in 2025, down 1785.38% in 2025.
- Tracing AURA's Other financing activities over 5 years: stood at $104000.0 in 2022, then tumbled by 30.77% to $72000.0 in 2023, then jumped by 654.17% to $543000.0 in 2024, then slumped by 2520.99% to -$13.1 million in 2025, then jumped by 100.94% to $123000.0 in 2026.
- The last three Other financing activities figures came in at $123000.0 (Q1 2026), -$13.1 million (Q3 2025), and $14.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.26 Mn |
| Jun 30, 2026 | 21.26 Mn |
| Mar 31, 2026 | 123,000.00 |
| Mar 31, 2026 | 123,000.00 |
| Sep 30, 2025 | -13.15 Mn |
| Sep 30, 2025 | -13.15 Mn |
| Jun 30, 2025 | 14.16 Mn |
| Jun 30, 2025 | 14.16 Mn |
| Dec 31, 2024 | 543,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Sep 30, 2024 | 780,000.00 |
| Sep 30, 2024 | 780,000.00 |
| Jun 30, 2024 | -63,000.00 |
| Jun 30, 2024 | -63,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | -89,000.00 |
| Jun 30, 2023 | -89,000.00 |